The Scientist

» mammals and disease/medicine

Most Recent

image: Bioethicist Resigns from CellTex

Bioethicist Resigns from CellTex

By | March 1, 2012

Bioethicist Glenn McGee, founder of the American Journal of Bioethics, resigned from a controversial stem cell company.

2 Comments

image: A Whiff of TB

A Whiff of TB

By | March 1, 2012

Bioethicist Glenn McGee, founder of the American Journal of Bioethics, resigned from a controversial stem cell company.

0 Comments

image: What it Takes to Develop Better Drugs for Kids

What it Takes to Develop Better Drugs for Kids

By | March 1, 2012

Bioethicist Glenn McGee, founder of the American Journal of Bioethics, resigned from a controversial stem cell company.

2 Comments

Contributors

March 1, 2012

Bioethicist Glenn McGee, founder of the American Journal of Bioethics, resigned from a controversial stem cell company.

0 Comments

image: Are the Kids Alright?

Are the Kids Alright?

By | March 1, 2012

Bioethicist Glenn McGee, founder of the American Journal of Bioethics, resigned from a controversial stem cell company.

6 Comments

Bioethicist Glenn McGee, founder of the American Journal of Bioethics, resigned from a controversial stem cell company.

12 Comments

image: Capsule Reviews

Capsule Reviews

By | March 1, 2012

Bioethicist Glenn McGee, founder of the American Journal of Bioethics, resigned from a controversial stem cell company.

4 Comments

image: How Drugs Interact with a Baby’s Parts

How Drugs Interact with a Baby’s Parts

By | March 1, 2012

Bioethicist Glenn McGee, founder of the American Journal of Bioethics, resigned from a controversial stem cell company.

0 Comments

image: Speaking of Science

Speaking of Science

By | March 1, 2012

Bioethicist Glenn McGee, founder of the American Journal of Bioethics, resigned from a controversial stem cell company.

6 Comments

image: Suspected Effects of Vitamin D

Suspected Effects of Vitamin D

By | March 1, 2012

Bioethicist Glenn McGee, founder of the American Journal of Bioethics, resigned from a controversial stem cell company.

0 Comments

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech